Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs provides a diverse range of anti-FASLG CAR products designed for the specific and effective targeting of cancers expressing FASLG. Our CAR products undergo rigorous quality control procedures to ensure their safety and effectiveness.
Fas ligand (FASLG), also known as CD95L or CD178, is a transmembrane protein that is primarily expressed on activated T cells and natural killer (NK) cells. FASLG plays a crucial role in apoptosis (programmed cell death) through its interaction with the Fas receptor. By modulating the FASLG pathway, it is possible to selectively induce cell death in cancer cells while sparing normal cells or to regulate immune responses in autoimmune diseases.
Dysregulation of FASLG signaling has been implicated in various diseases, including autoimmune disorders and certain types of cancer. Targeting FASLG in therapy holds promise for the development of novel treatment strategies with the potential to improve outcomes for patients with various diseases. Therapeutic approaches targeting FASLG may include the use of monoclonal antibodies, small molecule inhibitors, or gene therapy to either inhibit or enhance FASLG signaling based on the specific disease context.
Fig.1 Schematic of FAS-FASLG pathway.1
Associated Disease
We offer anti-FASLG CAR-T expression tests that are used to assess the expression and functionality of anti-FASLG CAR-T cells. The test typically involves techniques such as Western blotting (WB) and flow cytometry to analyze the expression levels of the CAR construct in the modified T cells.
CAR-T proliferation assays and techniques are utilized to measure the growth and expansion of CAR-T cells in cell culture. Our experts have rich experience in analyzing the proliferation kinetics of CAR-T cells. We provide anti-FASLG CAR-T proliferation test services that typically involve assessing the expansion and proliferation of CAR-T cells in response to specific stimuli or treatments.
Cytokine release tests are important for monitoring the activity and potential side effects of CAR-T cell therapy, as excessive cytokine release (known as cytokine release syndrome) can lead to serious adverse events in patients. At Creative Biolabs, we provide some common types of cytokine release tests such as ELISA, flow cytometry-based assays, and cytometric bead arrays that allow for the simultaneous detection and quantification of multiple cytokines in a single sample.
Our team of experts offers comprehensive CAR-T cytotoxicity testing services, tailored to meet the specific needs of our clients. We offer several different types of in vitro CAR-T cell cytotoxicity assays such as LDH release assay, Cr-51 release assay, and luminescence-based cytotoxicity assay.
By integrating diverse methods and techniques, Creative Biolabs is able to comprehensively evaluate the anti-tumor efficacy of candidates or therapies in a physiologically relevant context. We provide a variety of in vivo assays including anti-tumor efficacy studies, toxicity assessments, and CAR-T persistence studies.
Reference
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| CAR-0120ZP2347 | Anti-FASLG (Bmg2.3) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | Bmg2.3 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP2348 | Anti-FASLG (Bmg2.3) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | Bmg2.3 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP2378 | Anti-FASLG (FLIM4) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | FLIM4 | Hamster | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP2379 | Anti-FASLG (MFL3) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | MFL3 | Hamster | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP2380 | Anti-FASLG (MFL3) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | MFL3 | Hamster | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP2381 | Anti-FASLG (MFL4) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | MFL4 | Hamster | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP2382 | Anti-FASLG (MFL4) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | MFL4 | Hamster | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP2383 | Anti-FASLG (GM5F4) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | GM5F4 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP2384 | Anti-FASLG (GM5F4) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | GM5F4 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
| CAR-0120ZP2385 | Anti-FASLG (FLIM58) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | FLIM58 | Hamster | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
| XS-0622-ZP3290 | Anti-FASLG h(VHH1-VHH2-CD28-CD3ζ) Biepitopic CAR, pCDCAR1 | Human | VHH1-VHH2-CD28-CD3ζ | Lentiviral vector | T Cell | ||||
| XS-0622-ZP3462 | Anti-FASLG h(VHH1-VHH2-4-1BB-CD3ζ) Biepitopic CAR, pCDCAR1 | VHH1-VHH2-4-1BB-CD3ζ | Lentiviral vector | T Cell | |||||
| XS-0822-YF402 | Anti-Human FASLG (XW-402) h(41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-402 | Mouse | scFv-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF403 | Anti-Human FASLG (XW-403) h(41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-403 | Humanized | scFv-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF1321 | Anti-Human FASLG (XW-401) h(CD28-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-401 | Mouse | scFv-CD28-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF1322 | Anti-Human FASLG (XW-402) h(CD28-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-402 | Mouse | scFv-CD28-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF1323 | Anti-Human FASLG (XW-403) h(CD28-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-403 | Humanized | scFv-CD28-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF2241 | Anti-Human FASLG (XW-401) h(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-401 | Mouse | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF2242 | Anti-Human FASLG (XW-402) h(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-402 | Mouse | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF2243 | Anti-Human FASLG (XW-403) h(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-403 | Humanized | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
